Decisión del Panel Administrativo nº DCO2021-0067 of WIPO Arbitration and Mediation Center, September 29, 2021 (case Novartis AG v. Anonymize, Inc.)

Resolution DateSeptember 29, 2021
Issuing OrganizationWIPO Arbitration and Mediation Center
DominioColombia (.co)

WIPO Arbitration and Mediation Center


Novartis AG v. Anonymize, Inc.

Case No. DCO2021-0067

1. The Parties

The Complainant is Novartis AG, Switzerland, represented by Dreyfus & associés, France.

The Respondent is Anonymize, Inc., United States of America.

2. The Domain Name and Registrar

The disputed domain name [] (“Domain Name”) is registered with Epik, Inc. (the “Registrar”).

3. Procedural History

The Complaint was filed with the WIPO Arbitration and Mediation Center (the “Center”) on August 24, 2021. On August 24, 2021, the Center transmitted by email to the Registrar a request for registrar verification in connection with the Domain Name. On August 24, 2021, the Registrar transmitted by email to the Center its verification response disclosing registrant and contact information for the Domain Name, which differed from the named Respondent and contact information in the Complaint. The Center sent an email communication to the Complainant on August 25, 2021, providing the registrant and contact information disclosed by the Registrar, and inviting the Complainant to submit an amendment to the Complaint. The Complainant filed an amended Complaint on August 26, 2021.

The Center verified that the Complaint together with the amended Complaint satisfied the formal requirements of the Uniform Domain Name Dispute Resolution Policy (the “Policy” or “UDRP”), the Rules for Uniform Domain Name Dispute Resolution Policy (the “Rules”), and the WIPO Supplemental Rules for Uniform Domain Name Dispute Resolution Policy (the “Supplemental Rules”).

In accordance with the Rules, paragraphs 2 and 4, the Center formally notified the Respondent of the Complaint, and the proceedings commenced on August 31, 2021. In accordance with the Rules, paragraph 5, the due date for Response was September 20, 2021. The Respondent did not submit any response. Accordingly, the Center notified the Respondent’s default on September 22, 2021.

The Center appointed Nicholas Smith as the sole panelist in this matter on September 28, 2021. The Panel finds that it was properly constituted. The Panel has submitted the Statement of Acceptance and Declaration of Impartiality and Independence, as required by the Center to ensure compliance with the Rules, paragraph 7.

4. Factual Background

The Complainant is a company based in Switzerland, formed in 1996 through a merger though its predecessor companies have existed in various forms for over 250 years. The Complainant develops, manufactures and distributes a variety of pharmaceutical products and healthcare solutions. The Complainant’s products are available in over 155 countries and are used to treat over 750 million people globally. One of the Complainant’s best-known products is a non-steroidal anti-inflammatory drug known as Voltaren, which has been offered in various forms...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT